Next generation microbe-based therapeutics, inspired by the success of fecal microbiota transplants, are being actively investigated in clinical trials to displace or eliminate pathogenic microbes to treat various diseases in the gastrointestinal tract, skin, and vagina. Genetically engineered microbes are also being investigated in the clinic as drug producing factories for biologic delivery, This review will discuss examples of past and current clinical trials that are investigating microbetherapeutics, both microbiome-modulating and drug-producing, for the treatment of a range of diseases. We then offer a perspective on how preclinical approaches, both those focused on developing advanced delivery systems and those that use in vitro microbiome model systems to inform formulation design, will lead to the realization of next-generation microbe-therapeutics.
| I N TR ODU C TI ON
The human body coexists with microbiota, or communities of microbes, within the gastrointestinal (GI) tract, mouth, skin, vagina, and other tissues. 1 Each distinct microbiome, which encompasses the microbiota and their genetic material, balances key microbial populations in these tissues to regulate both health and disease. 2 An imbalance in these populations, or dysbiosis, in the GI tract may contribute to or result from cancer, obesity, diabetes, Clostridium difficile infection, or depression, among others. [2] [3] [4] Vaginal dysbiosis can lead to recurrent infections, increased risk of HIV transmission, preterm birth, or pelvic inflammatory disease. 5 Skin diseases such as dermatitis, and oral diseases such as caries are also significantly impacted by the microbiota. 6, 7 Efforts to identify and describe the key role specific microbes have in these conditions are at the forefront of biological and medical research. 4 This knowledge will be essential to translate mechanistic understandings of the impact of commensal microbes on human health to the effective implementation of microbes as therapeutics.
Two main therapeutic uses of microbes are being investigated in the clinic. The first involves displacing pathogenic microbes and restoring symbiosis in patients via the delivery of living therapeutic bacteria.
The second involves genetically programming microbes to secrete therapeutics, either locally at sites of disease or through biological barriers for systemic absorption. In either case, the delivery of these microbes must occur appropriately to provide a therapeutic benefit. Therefore, their design must account for delivery challenges of live microbe therapeutics, which include: (a) environmental factors (e.g., acid, enzymes, UV-light) that can impair microbe viability, deactivate the secreted biologic, or induce damage that limits their efficacy, (b) biological barriers (e.g., mucus, existing microbiota, lumen contents) that physically prevent interactions (e.g., engraftment, drug diffusion), and (c) achieving a suitable residence time at the site of action (e.g., duodenum for drug absorption 8 ). Unfortunately, the interactions between the commensal microbiota, the delivered microbe-therapeutic, and the host environment remain opaque and stand as a bottleneck to the rational design of delivery approaches for microbe-based therapeutics. Future research in microbe-therapeutics will require a focus on elucidating these mechanisms of action in order to rationally design delivery approaches.
In this review, we will give an overview of the current approaches to therapeutic microbiome modulation and the advantages that microbe-based therapeutics may have over current treatment options.
The current clinical landscape of microbe-therapeutics will be highlighted by reviewing clinical trials that utilize bacteria as therapeutics, which includes examples of bacteria both as tools to modulate the microbiome and as drug-producing factories. Next, we will focus on recent examples of formulation approaches that have improved microbe delivery. Finally, we will end with a perspective on how microbiome model systems can be used to inform the rational design of next-generation microbe-based therapeutics.
| M I CR OBE -BA SED TH E RA P EU T I CS F OR M I CR OBI OM E M ODU L A TI ON
Here, we will highlight current clinical studies where bacteria are used to modulate the GI, skin, and vaginal microbiomes. It is worth noting that oral probiotics regulated as dietary supplements, rather than as therapeutics, do not require extensive clinical data to support functional claims. 9 While investigational clinical trials aimed at understanding the action of these dietary supplements and probiotics are underway, they will not be discussed here as they have been reviewed elsewhere. 10 
| Current approaches to microbiome modulation
The most effective and established method for altering microbiota compositions are antibiotics, which are often a first-line treatment for bacterial infections. 11 Antibiotics have prevented countless deaths and are mainstays in clinical care. However, instances of antibiotic use have recently been linked to negative clinical outcomes. For example, the use of broad-spectrum antibiotics can lead to dysbiosis by disrupting the commensal microbiota 12 and their overuse has contributed to the rise of antibiotic-resistant pathogens. 13, 14 By creating a commensalfree environment containing antibiotic-resistant pathogens, antibiotics often promote more-severe, recurring infections 15, 16 as is the case for recurrent C. diff infections (RCDI). 17, 18 These risks, particularly with RCDI, have generated significant interest in developing alternative therapies that mitigate the killing of commensal bacteria and the evolution of antibiotic-resistant pathogens. 15, 19 One potential alternative are bacterial viruses (phage), which infect bacteria, propagate in their bacterial-hosts, lyse the bacteria, and are then released into the local environment (e.g., intestinal lumen) to continue this cycle. 20 Phages are highly specific to bacterial strains and can be used to exclusively eliminate enteric pathogens, while sparing commensal bacteria; this has motivated research into their use for the treatment of antibioticresistant pathogens. [21] [22] [23] However, the clinical translation of phagebased therapies has been minimal due to challenges related to their purification, characterization, and regulation. [24] [25] [26] [27] Furthermore, due to the complex evolutionary dynamics between phage and bacteria, pathogens may become resistant to phage infection and lysis, which limits their long-term and repeated use. 28 Other alternative approaches, such as inorganic metals, antimicrobial peptides, and gene editing enzymes (e.g., CRISPR-Cas9) are also being developed, 29 but
will not be reviewed here as they are not yet widely used in the clinic.
| Fecal transplant-based approaches for gut microbiome modulation
Microbe-therapeutics for microbiome modulation aim to displace colonized pathogens through competitive metabolic interactions, niche exclusion, or initiation of host immune responses. 30 In doing so, microbe-therapeutics have the potential to address the challenges facing antibiotics as outlined above. 31 The best example of these therapies are fecal microbiota transplants (FMTs), which take fecal bacteria from a healthy donor and transplant it into the GI tract of a dysbiotic or diseased individual, typically through colonoscopy or nasal tube infusion. 32, 33 FMTs are one of the only clinical methods for treating RCDI, 34 which occurs in 15-30% of patients after taking the standard regimen of antibiotics, 19 and have been up to 90% effective in multiple clinical studies. 27, [35] [36] [37] modulation. Additionally, the authors conducted phylum-level classification of microbiota engraftment to confirm that the patient's microbiota compositions following treatment shifted towards the donor's composition ( Figure 1a ). 46 Microbe engraftment was determined on multiple days in the first month and was monitored for up to a year after the study. By using multiple comparative points within the study, this is a stronger assessment of engraftment and cannot be attributed to the formulation residence time in the GI tract. This data, and other data not highlighted here, 47, 48 were used to validate a predictive model of FMT microbe engraftment, which included factors such as the composition of donor samples, the elapsed time since the transplant, type and duration of antibiotics, and route of administration. 49 ; however, in stark contrast, SER-109 did not significantly reduce the RCDI in a Phase 2 trial. 53 Seres Therapeutics proceeded with a Phase 3 trial of SER-109 for the treatment of RCDI 54 as they believed that the lack of efficacy in Phase 2 was related to dosing and patient selection issues that can be resolved in their current trial. 53 Recently, the results from SER-109 inspired the rational design of SER-262, which consists of 12 strains of bacterial spores that both engrafted in SER-109 patients and were prevalent in the original donor samples. SER-262 is grown via in vitro fermentation, which could eliminate the use of donor-derived FMTs altogether, reducing safety concerns and standardizing formulations.
Currently SER-262 is in a Phase 1b clinical trial for RCDI (Table 1) . 49 however, it is still unclear whether microbe engraftment necessarily correlates with therapeutic efficacy. Moving forward, the ability to identify these key factors, develop approaches to study them, and design formulations that consider them will be essential to the rational design of oral FMT therapeutics.
| Vaginal microbiome modulation
There are fewer examples of clinical trials in microbiome modulation for the vaginal tissue ( and reduced urinary tract infections by nearly half. 62 In efforts to understand how external factors and microenvironment conditions influence colonization, the clinical trials also concluded that presence of bacterial vaginosis-associated bacteria, 63 exposure to semen, vaginal intercourse, and the presence of Lactobacillus all reduced colonization of LACTIN-V. 64 LACTIN-V was originally delivered via gelatin capsule, which was later switched to a proprietary applicator. Interestingly, this formulation change was inspired by an early study that postulated that colonization of LACTIN-V was impaired by the slow release from the gelatin capsules in the vagina. 60 While not directly investigated, this points to the importance of formulation design for the delivery of live-microbes.
In other work, an effervescent tablet was used to encapsulate and deliver Lactobacillus fermentum and Lactobacillus acidophilus for the treatment of vulvovaginal candidiasis in humans. The two Lactobacillus strains were selected as they exhibited significant in vitro inhibition against four different Candida species that are associated with vulvovaginal candidiasis. The motivation for the use of an effervescent tablet was twofold: first, the slow release from the tablets was expected to enhance adhesion and subsequent colonization to the vaginal epithelium and second, the release of CO 2 would create an anaerobic environment that is more favorable to the Lactobacillus strains. 65 Unfortunately, the formulation was not directly compared to an effervescent-free tablet control. Still, this work highlights how a formulation approach can enable favorable environmental conditions (i.e., anaerobic conditions) that improve microbe survival, colonization, and efficacy. In a follow-up study in 58 patients, it was shown that this formulation achieved over 70%
inhibition of clinical recurrence. 66 Overall, these studies and clinical trials highlight the importance of considering patient habits, microbiota variability, health status, and even the delivery system for microbiome-modulating therapies for bacterial infections in the vagina. These considerations may be extended to the dermal microbiome, where microbes are also delivered topically.
| Dermal microbiome modulation
Similar to vaginal microbiome modulation applications, topical dermal microbiome modulation (Table 2) 
| BA CTE R IA A S D R U G P R ODU C IN G AN D DE L IV E RI N G V E HI C LE S
The use of bacteria to produce drugs has been a longstanding, essential cornerstone of the pharmaceutical industry 70, 71 and has been investigated in clinical trials for in vivo therapeutic production and delivery (Table 3) . Since the genetic engineering of bacteria for therapeutic applications has been reviewed elsewhere, 72, 73 we will focus on clinical examples and discuss opportunities for a formulationbased approach to improve delivery by considering microenvironment interactions.
In 2006, to the best of our knowledge, the first clinical trial utilizing genetically engineered bacteria to deliver drugs in humans described an engineered Lactococcus lactis (L. lactis) strain that secreted IL-10 for the treatment of Crohn's disease. Results from the trial showed that the oral capsule-delivered therapy was well tolerated and that multiple patients showed complete remission of Crohn's disease (Figure 2a) . 74 An important consideration in this study was to ensure biological containment to avoid the potential health-risks that could occur if this strain were to stably colonize the patient, be excreted, and subsequently enter the environment. As such, the strain was engineered to require a thymine-rich environment for survival, thus it would pose little risk if the bacteria were to escape the human host. In a follow up Phase 2 clinical study, this strain did not show a statistically significant benefit compared to a placebo. 75 The low efficacy in the follow up study may be attributed in part to DNA degradation during GI transit, observed during the Phase 1 trial, 74 or the inability for IL-10 to penetrate intestinal mucosal barriers. The prior concern may be mitigated with a more advanced delivery strategy, such as an enteric capsule, Oragenics is developing a genetically engineered L. lactis strain designed to secrete trefoil factor (AG013) that is being investigated in a Phase 2 clinical trial as a mouth rinse formulation for the treatment of oral mucositis. A Phase 1b trial with this product showed a 35% reduction of ulcerative mucositis following mouth rinse administration up to six times daily (Figure 2b ). 76 Importantly, extensive preclinical data demonstrated that both the L. lactis and secreted trefoil factor were limited to the site of administration, and were undetectable systemically, indicating a low risk of systemic exposure and toxicity. 77, 78 The clinical success built on preclinical work that optimized oral dosing regimens, described the pharmacokinetics, and investigated the persistence of the bacteria both systemically and locally for safety implications after topical administration. 77, 78 It appears that fewer challenges related to the microenvironment exist for AG013; as such, it is not clear if a formulation-based approach would improve efficacy in this case. Marina Biotech has finished a Phase 1 trial with CEQ508, an engineered Escherichia coli (E. coli) strain that produces and delivers b-catenin short-hairpin RNA, a challenging to deliver biologic, into the mucosa for patients with familial adenomatous polyposis. Results from the Phase 1 trial showed significant knockdown in b-catenin throughout the GI tract and the strain was well tolerated. The completion of this trial made CEQ508 the first clinically tested, orally administered RNAi-based drug. Marina Biotech has received Orphan Drug Status and Fast Track Designation for CEQ508. 79 In other clinical studies, genetically engineered strains for cancer treatment or prevention are also being investigated ( Table 3 ).
The delivery requirements are much clearer for drug-producing bacteria therapies, as compared to their microbiome-modulating counterparts, since the site of action and properties of the delivered drug are well known. As such, formulation-based approaches that can increase resistance to environmental challenges (e.g., an enteric capsule), residence time (e.g., mucoadhesive formulations), and localization to either the diseased tissue or the site of absorption will improve delivery. Since the majority of these genetically engineered strains secrete biologics that have been notoriously difficult to stabilize and deliver in vivo, 80 formulation approaches can also be used to protect both the bacteria and biologic drug. Furthermore, if biologics are to be absorbed systemically, approaches to increase residence time at the relevant absorption site (e.g., duodenum) will also improve biologic delivery.
| P RE CL I NI CA L A P P ROA CH ES TO I M P ROV E M IC ROB E-D EL I VE RY
While delivery approaches for microbes are still in their infancy, methods that improve survival, control transit and residence time, and target specific sites can ensure that microbes arrive at the right place, at the right time, and in the right concentration. In the case of drug-secreting bacteria, these functions will enable better drug transport either to the local pathology or across biological barriers for systemic absorption.
Similarly, for bacteria that modulate the microbiome, advanced formulations can offer improved delivery to the target site; however, whether these advantages lead to enhanced efficacy remains an open question as these formulations have not been explored rigorously and not enough is known about the microbe's mechanism of action. Here, we will highlight preclinical studies that have demonstrated how formulation approaches can improve the delivery of microbes. We will then offer a perspective on how preclinical in vitro models can aid in informing formulation design, especially for microbiome modulation applications.
| Formulation for improved delivery
There are a number of approaches to improve microbe delivery in both (Table 1 ). The study established that oral capsule delivery of FMTs is non-inferior as compared to standard colonoscopy. Furthermore, patients who received capsules exhibited similar increases in the taxonomic composition prior to and after treatment. 81 While these results clearly support oral delivery as an effective option for FMTs, they also highlight the need for advanced formulation approaches. In this study, patients were required to ingest 40 capsules of FMT equivalent, 81 an extreme pill burden that could be reduced through more efficient delivery. This may be achieved by designing microbe therapeutics that can (a) intentionally interact with multiple environmental factors in the host and (b) be combined with the current state of the art (capsules) to synergistically improve microbe delivery.
Two examples of preclinical delivery systems that modify individual microbes to be more resistant to environmental challenges and specifically interact with the microenvironment are highlighted in this section.
Formulations that are resistant to challenges will have improved microbe survival and formulations that interact directly with the microenvironment can allow for spatiotemporal control over microbe release which may have implications for engraftment efficiency. While both of these examples improve delivery to the GI tract, their delivery principles still apply to the vaginal, dermal, or oral tissues. For example, these tissues will need to consider residence time, a critical parameter that will dictate therapeutic efficacy and is mediated by environmental conditions such as self-cleaning in the vagina, 82 enzymatic degradation and saliva production in the oral cavity, 83 and external physical interactions on the skin.
The modifications to the surface of individual bacteria have been shown to improve survival and delivery through the GI tract. A layerby-layer (LbL) encapsulation approach was used to improve the delivery of Bacillus coagulans (B. coagulans) to the GI tract. In this study, mucoadhesive polysaccharides, chitosan, and alginate, were shown to protect against acidic stomach conditions and bile salts in the intestines when used as consecutive coatings on the surface of B. coagulans (Figure 3a) . The LbL coating additionally improved B. coagulans mucoadhesion to fresh porcine intestine (Figure 3b ) and improved the short-term growth of B. coagulans on a human intestine model. Taken together, these results imply that mucoadhesion can alter the growth kinetics of the delivered microbe on the mucosal surface. Controlling growth and proliferation at the site of interest can improve engraftment and lower the required dose by increasing bioavailability in the intestine. When this LbL formulation was tested in vivo, a sixfold enhancement in the delivery of viable B. coagulans to the intestines, as compared to nonencapsulated B. coagulans, was observed (Figure 3c ). It was not clear whether improved resistance to acid and bile salts or the enhanced binding to, and growth on, mucus was predominantly responsible for improved delivery. 84 In any case, improved delivery was achieved using a formulation approach that modified the surface of the microbetherapeutic. It is reasonable to assume that these microbe modifications can be combined with the standard formulation, an oral capsule.
This work clearly highlights the potential for using pharmaceutical formulation approaches to better control interactions with both the chemical and physical environments to improve live-microbe delivery.
In a separate work, E. coli Nissile 1917 (Eda) was genetically engineered to treat colorectal cancer (CRC) locally in the GI tract. 85 The authors considered the CRC microenvironment, such as surface receptors on cancer cells, and the GI tract environment, such as ingested food, to optimize their formulation. The final formulation (Figure 4a ), (Figure 4c) . Surprisingly, despite doubling the attachment of Eda microbes, the targeted therapy did not exhibit significant differences in tumor treatment as compared to the non-targeted therapy (Figure 4c ). However, serum concentrations of the systemically absorbed drug product were significantly higher (twofold) for animals treated with targeted Eda (Figure   4d ). This finding indicates that the enhanced attachment of Eda-I1-HlpA microbes to the tumor led to either increased production or absorption of sulforaphane. Given this discrepancy between increased drug concentrations and therapeutic efficacy, it is possible that a targeted approach is not necessary to achieve maximum tumor eradication ( Figure 4c ) in this model. However, since the targeted group led to a twofold enhanced systemic drug product (Figure 4d) , it is clear that targeting will provide benefits for other applications, including genetically engineered microbes that secrete drugs for systemic absorption.
This work presents evidence that genetically engineering microbes designed to interact with both the local tumor microenvironment (i.e., surface receptors on cancer cells) and the GI environment (i.e., soluble dietary glucosinolate) can enhance aspects of microbe delivery which can lead to improved therapeutic outcomes. 90 In addition to determining compositions of the microbiota that can act prophylactically to reduce viral transmission, these models can be used to isolate specific therapeutic strains to improve disease.
| Microbiome model systems to inform formulation
Recently, ileal samples from patients suffering from Crohn's disease were used to screen a variety of microbes, leading to the identification of strains that reduce inflammation. 91 addition to the static features listed above. These models are essential to determine the therapeutic efficacy of a certain formulation or combination treatment. For example, a microfluidic gut-on-a-chip ( Figure   5c ) was used to investigate how antibiotics and therapeutic microbes can treat intestinal inflammation from enteroinvasive E. coli (Figure 5d ).
The chip mimicked the key features of the GI tract such as the intestinal barrier properties, intestinal morphology (Figure 5e ), anaerobic conditions, shear stress, and peristaltic forces. 92, 93 Concomitant administration of the therapeutic microbes and antibiotics protected against lesion formation caused by pathogenic E. coli (Figure 5f ). 94 Furthermore, the system was used to show how colonization of specific therapeutic microbes under physiological conditions prevents the inflammation caused by exposure to pathogenic bacteria. Individual aspects of this physiological model could be turned on or off (Figure   5f ), which allows for isolation of the key contributing factors; in this case, the distinct beneficial contributions of therapeutic microbes and antibiotics could be tested independently. LbL coating, for example, the relative importance of mucoadhesive or protective properties could be determined using a model that can individually examine mucus and gastric fluid interactions. Although it is nearly impossible to confirm that these models accurately recreate in vivo conditions, they can enable analyses of the microenvironment that are not possible in vivo or in humans, including host cell molecule secretion, microbe viability in the presence of various conditions, therapeutic microbe effects in a disease model, and dynamic forces that are relevant to the microbiome. Additionally, both dynamic and static systems offer the option to source samples directly from patients, which can yield clinically relevant insights toward personalized applications or toward understanding specific pathologies. Studies using patient microbiota samples can also enable evaluations of the effect of interpatient variability due to age, geographical location, and ethnicity 95, 96 that has been observed in clinical trials. 52, 97 It is clear that preclinical models will be a powerful tool to identify which, if any, microenvironment factors impact microbe efficacy and delivery. Even if few relevant microenvironment conditions are identified, these models can be used to understand the effective components and mechanisms of action of a therapeutic formulation.
| Preclinical outlook

| CON CL U S I ONS
Clinical trials have proven the potential for bacteria to offer alternative clinical treatment for a variety of diseases, through the secretion and delivery of challenging therapeutics, as well as the modulation of the microbiota composition toward symbiosis. As the development of livemicrobe therapeutics progresses, it will become necessary to consider the interactions these therapies have with the host microenvironment.
Since the importance of having control over where, when, and how a drug interacts with the diseased site has been shown to be a defining success criteria for all other forms of drugs, it should be a primary con- addressing these open questions is also unclear. Therefore, this knowledge gap must be addressed, potentially through static and dynamic in vitro models, before rational formulation design can be used to increase therapeutic microbe efficacy. As understandings of relevant microenvironment interactions and challenges increase, opportunities to translate this knowledge to delivery platforms that can increase microbe viability, residence time, stability, and efficacy will become clearer. We envision that current research will enable (a) the determination of which strains are responsible for displacing specific pathogens, (b) the use of in vitro model systems to study phenomena that can inform therapy design, and (c) the development of a toolkit to functionalize, engineer, and package bacteria such that they interact in specific ways with the local microenvironment. This new area will require a fundamental understanding of how these therapies treat disease and a simultaneous effort to improve delivery.
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